Edra
European Annals of Allergy and Clinical Immunology THE OFFICIAL JOURNAL OF AAITO THE OFFICIAL JOURNAL OF SPAIC HOME PAGE
2022 Impact Factor
2.3
EDITORS IN CHIEF
M. B. Bilò (Italy)
P. Carreiro-Martins (Portugal)

DEPUTY EDITORS
R. Rodrigues Alves (Portugal)
D. Villalta (Italy)
 
ASSOCIATE EDITORS
R. Asero (Italy)
M. Branco Ferreira (Portugal)
L. Cecchi (Italy)
E. Scala (Italy)
D. Solé (Brasil)
G. Sturm (Austria)

EDITORIAL BOARD
I. Agache (Romania)
I. Annesi Maesano (France)
L. Antonicelli (Italy)
G. Azizi (Iran)
L.M. Borrego (Portugal)
K. Brockow (Germany)
S. Bavbek (Turkey)
E. Cichocka-Jarosz (Poland)
M. Cugno (Italy)
L. Delgado (Portugal)
P. Demoly (France)
G. D'Amato (Italy)
S. Durham (UK)
M. Faber (Belgium)
M. Fernandez-Rivas (Spain)
J. Fonseca (Portugal)
ZS. Gao (China)
G.P. Girolomoni (Italy)
E. Goudouris (Brasil)
A. Grumach (Brasil)
G. Kostantinou (Greece)
F. Levi-Shaffer (Israel)
M. Maurer (Germany)
L. Mayorga (Spain)
C. Micheletto (Italy)
M. Morais de Almeida (Portugal)
G. Moscato (Italy)
A. Musarra (Italy)
C. Nunes (Portugal)
M. Ollert (Lussemburgo)
P. Parronchi (Italy)
G. Passalacqua (Italy)
E. Pedro (Portugal)
A. Perino (Italy)
O. Quercia (Italy)
A. Romano (Italy)
G. Scadding (UK)
A. Todo Bom (Portugal)
A. Tedeschi (Italy)
R. van Ree (Netherland)
S. Voltolini (Italy)

FOUNDERS
F. Bonifazi (Italy)
A. Sabbah (France)
************************* 

Chief Executive Officer 
Ludovico Baldessin

Editorial Coordinator
Barbara Moret

Publishing Editor
Jessica Guenzi
j.guenzi@lswr.it

Sales
dircom@lswr.it

EDRA SpA 
Via G. Spadolini, 7
20141 Milano - Italy
Ph. 0039 (0)2-88184.1
Fax 0039 (0)2-88184.301
www.edraspa.it


Follow us on LinkedIn



European Annals of Allergy and Clinical Immunology ISSN 1764-1489

© 2024

Contents »

Primary immunodeficiency disorders in children with Non-Cystic Fibrosis Bronchiectasis


D. Çağdaş cagdasdenizna@yahoo.com1, M. Pehlivantürk Kızılkan2, A. Tagiyev2, N. Emiralioğlu3, A. Keleş4, E. Yalçın3, D. Doğru3, U. Özçelik3, N. Kiper3, İ. Tezcan1

Show more: Authors information and Publication history

Doi
http://doi.org/10.23822/EurAnnACI.1764-1489.151

Summary
Introduction. Primary Immunodeficiency diseases(PID) are common in patients with non-cystic fibrosis bronchiectasis(NCFB). Our objective was to determine ratio/types of PID in NCFB. Patients. Seventy NCFB patients followed up in a two-year period were enrolled. Results. Median age was 14 years (min.-max., 6-30). Patients had their first pulmonary infection at a median age of 6 months(min.-max., 0.5-84), were diagnosed with bronchiectasis at about 9 years(114 months)(min.-max., 2-276)). Male/female ratio was 39/31; parental consanguinity, 38.6%. PID, primary ciliary dyskinesis (PCD), bronchiolitis obliterans, rheumatic/autoimmune diseases, severe congenital heart disease and tuberculosis were evaluated as the most common causes of NCFB. About 40% of patients (n=16) had bronchial hyperreactivity(BH) and asthma. Twenty-nine patients(41.4%) had a PID, and nearly all (n=28) had primary antibody deficiency, including patients with combined T and B cell deficiency. PID and non-PID groups did not differ according to gender, parental consanguinity, age at first pneumonia, age of onset of chronic pulmonary symptoms, bronchiectasis, presence of gastroesophageal reflux disease(GERD), bronchial hyperreactivity(BH) and asthma (p>0.05). Admission to immunology clinic was about 3 years later in PID compared with non-PID group(p<0.001). Five patients got molecular diagnosis, X-linked agammaglobulinemia(n=2), LRBA deficiency(n=1), RASGRP1 deficiency(n=1), MHC Class II deficiency(n=1). They were given monthly IVIG and HSCT was performed for three patients. Conclusions. PID accounted for about 40% of NCFB. Early diagnosis/appropriate treatment have impact on clinical course of a PID patient. Thus, follow-up in also immunology clinics should be a routine for patients who experience pneumonia in the first year of their lives and those with NCFB. Most patients with NCFB (84.28%) had their first pulmonary infection within the first year of their lives.

Key words
Non-Cystic Fibrosis Bronchiectasis, primary immunodeficiency, bronchiectasis, respiratory infections

FULL TEXT